Please assess the completion status of the following clinical trial:

Trial Title: STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Main phase:~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Body mass index (BMI) greater than or equal to 30.0 kg/sqm or greater than or equal to 27.0 kg/sqm with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Extension phase:~* Informed consent for the extension phase obtained before any trial related activities for the extension phase~* On randomised treatment on the target dose at week 68, i.e. treated with 2.4 mg semaglutide once-weekly or semaglutide placebo~Exclusion Criteria:~Main phase:~* Glycated haemoglobin (HbA1C) greater than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records~Extension phase:~* Female who is pregnant or intends to become pregnant during the extension phase~* Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardise the subject's compliance with the extension of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide s.c. 2.4 mg once weekly (Type: EXPERIMENTAL): Participants will receive semaglutide for 68 weeks.
- Semaglutide placebo (Type: PLACEBO_COMPARATOR): Participants will receive semaglutide matching placebo for 68 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).